MapLight Therapeutics closed at $6.71 on Nov 4, down 1.47%, within 0.0% of its 52-week closing low. Volume of 389.9K shares was 1.11× its 20-day average (close to normal).
Split-adjusted performance: -30.8% over one month, -76.9% over six months, -60.3% over one year.
Short interest was 3.3M shares at the Oct 15 settlement, up 5.5% from the prior report (24.6% of float, 8.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MPLTMapLight Therapeutics | $6.71 | −1.47% | −76.9% | — | — | — | $372.9M | |
| CTNMContineum Therapeutics | $9.79 | +1.03% | −34.5% | — | — | — | $368.3M | Compare |
| LYELLyell Immunopharma | $15.43 | +43.27% | −26.0% | −50.0% | −1118875.0% | — | $378.1M | Compare |
| AVTXAvalo Therapeutics | $7.07 | −2.48% | −67.6% | — | — | — | $379.2M | Compare |
| RZLTRezolute, Inc. Common Stock (NV) | $3.96 | −1.25% | +26.1% | — | — | — | $383.0M | Compare |
| AVIRAtea Pharmaceuticals | $4.46 | +6.95% | −21.1% | — | — | — | $357.7M | Compare |
| IRDOpus Genetics | $4.27 | +8.65% | −18.8% | −73.8% | −1072.6% | — | $355.2M | Compare |
| BLSMBlossomHill Therapeutics | $12.38 | −0.24% | — | — | — | — | $393.5M | Compare |
| GALTGalectin Therapeutics | $3.47 | +3.58% | +54.2% | — | — | — | $349.9M | Compare |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
